EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Tony Mok iD, Kazuhiko Nakagawa iD, Keunchil Park iD, Yuichiro Ohe iD, Nicolas Girard, Hye Ryun Kim iD, Yi-Long Wu iD, Justin Gainor iD, Se-Hoon Lee iD, Chao-Hua Chiu iD, Sang-We Kim, Cheng-Ta Yang iD und 11 weitere

Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1252-1264

DOI: 10.1200/jco.23.01017 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Tony Mok und 22 weiteren Autor:innen. Beteiligte Einrichtung: State Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251 ) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor ( EGFR)–mutated metastatic non–small-cell lung cancer (NSCLC) after disease progression on EGFR tyrosine kinase inhibitors (TKIs). METHODS Patients with disease progression after first- or second-generation EGFR TKI therapy (without EGFR T790M mutation) or osimertinib (with/without T790M mutation) were randomly assigned 1:1 to nivolumab (360 mg once every 3 weeks) plus platinum-doublet chemotherapy (once every 3 weeks) or platinum-doublet chemotherapy alone (once every 3 weeks) for four cycles. Primary end point was progression-free survival (PFS). Secondary end points included 9- and 12-month PFS rates, overall survival (OS), objective response rate (ORR), and duration of response (DOR). RESULTS Overall, 294 patients were randomly assigned. At final analysis (median follow-up, 38.1 months), PFS was not significantly improved with nivolumab plus chemotherapy versus chemotherapy (median, 5.6 v 5.4 months; hazard ratio [HR], 0.75 [95% CI, 0.56 to 1.00]; P = .0528), with 9- and 12-month PFS rates of 25.9% versus 19.8%, and 21.2% versus 15.9%, respectively. Post hoc PFS subgroup analyses showed a trend favoring nivolumab plus chemotherapy in patients with tumors harboring sensitizing EGFR mutations (HR, 0.72 [95% CI, 0.54 to 0.97]), one line of previous EGFR TKI (0.72 [95% CI, 0.54 to 0.97]), or both (0.64 [95% CI, 0.47 to 0.88]). Median OS was 19.4 months with nivolumab plus chemotherapy versus 15.9 months with chemotherapy, while ORR was 31.3% versus 26.7%, and median DOR was 6.7 versus 5.6 months, respectively. Grade 3/4 treatment-related adverse events occurred in 44.7% and 29.4% of patients treated with nivolumab plus chemotherapy and chemotherapy alone, respectively. CONCLUSION Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionErbB ReceptorsMutationNivolumabPlatinumProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Substanzen

ErbB ReceptorsNivolumabPlatinumProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • State Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
  • Kindai University Faculty of Medicine, Osaka, Japan.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • National Cancer Center Hospital, Tokyo, Japan.
  • Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.

ORCID-Profile: Tony Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Hye Ryun Kim, Yi-Long Wu, Justin Gainor, Se-Hoon Lee, Chao-Hua Chiu, Cheng-Ta Yang, Lin Wu, Jens Samol, Mengzhao Wang, James Chih-Hsin Yang

Zitieren

APA

Mok, T., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y. L., Gainor, J., Lee, S. H., Chiu, C. H., Kim, S. W., Yang, C. T., Wu, C. L., Wu, L., Lin, M. C., Samol, J., Ichikado, K., Wang, M., Zhang, X., …, & Yang, J. C. (2024). Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of Clinical Oncology, 42(11), 1252-1264. https://doi.org/10.1200/jco.23.01017

Vancouver

Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. Journal of Clinical Oncology. 2024;42(11):1252-1264. doi:10.1200/jco.23.01017

BibTeX
@article{Mok2024,
  author = {Mok, Tony and Nakagawa, Kazuhiko and Park, Keunchil and Ohe, Yuichiro and Girard, Nicolas and Kim, Hye Ryun and Wu, Yi-Long and Gainor, Justin and Lee, Se-Hoon and Chiu, Chao-Hua and Kim, Sang-We and Yang, Cheng-Ta and Wu, Chien Liang and Wu, Lin and Lin, Meng-Chih and Samol, Jens and Ichikado, Kazuya and Wang, Mengzhao and Zhang, Xiaoqing and Sylvester, Judi and Li, Sunney and Forslund, Ann and Yang, James Chih-Hsin},
  title = {Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {11},
  pages = {1252--1264},
  doi = {10.1200/jco.23.01017}
}
Kostenlos starten →